Quarterly report pursuant to Section 13 or 15(d)

4. Commitments and Contingencies (Details Narrative)

v3.21.1
4. Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended
Feb. 06, 2021
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Research and development expense   $ 2,206,874 $ 613,077  
Other receivable - related party   132,648   $ 0
Mr. Climaco [Member]        
Salary and wages $ 525,000      
Silberman [Member]        
Salary and wages 200,000      
Picker [Member]        
Salary and wages 115,000      
Mr. Downs [Member]        
Salary and wages $ 340,000      
Technology Rights And Development Agreement [Member] | Houston Pharmaceuticals [Member]        
Royalty income   87,500 50,000  
Patent and Technology License Agreement [Member] | UTMDACC [Member]        
Contractual obligation   200,000    
License fee   22,902    
Sponsored Research Agreement [Member] | UTMDACC [Member]        
Contractual obligation     $ 734,000  
Research and development expense   400,000    
WPD Product Supply Agreement [Member] | Upfront Payment [Member]        
Other receivable - related party   131,073    
WPD Product Supply Agreement [Member] | Pass through costs [Member]        
Other receivable - related party   $ 1,575